Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institutes of Health is forecasting a Notice of Funding Opportunity for the Gabriella Miller Kids First Pediatric Research Program, specifically focusing on the Genome Sequencing Center initiative. This program aims to advance the understanding of childhood cancer and congenital anomalies by discovering shared genetic pathways and disease mechanisms to develop targeted therapies. The initiative will fund the expansion of data types, the addition of new data to the resource, and the integration of clinic-based data sources. This opportunity will utilize the U24 activity code and does not allow for clinical trials. While applications are not currently being solicited, the notice serves to allow investigators with expertise in childhood cancer and congenital abnormalities to establish collaborations and develop responsive projects. The project falls under NAICS code 541714 and is managed by the Department of Health and Human Services.

General Info

NIH upcoming funding for pediatric cancer and congenital research, genome sequencing focus, no clinical trials.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUSA
Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health
Office AddressUSA
Contacts
Concepcion R. Nierras Ph.D. Office of Strategic Coordination
contact@example.gov
+1 (555) 000-0000

Full Description

Show more

The NIH Common Fund, with other NIH Institutes and Centers (ICs), intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the Gabriella Miller Kids First Pediatric Research Program (Kids First), which seeks to help researchers uncover new insights into the biology of childhood cancer and congenital anomalies, including the discovery of shared genetic pathways between these disorders, to understand the underlying mechanisms of disease and ultimately lead to more targeted therapies and interventions for patients and families. The program’s Genome Sequencing Center initiative will fund adding data to the resource, expanding data types as technologies mature and scientific rationale warrant, and expanding to add clinic-based data sources. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U24 activity code. Investigators with expertise and insights into childhood cancer and/or congenital abnormalities data are encouraged to begin to consider applying for this new NOFO. 

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.
Rpo East (36C24E)

POSTED

1 day ago

DEADLINE

in 13 days
View Details
NAICS: 541714
New
Federal
AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.
Rpo East (36C24E)

POSTED

1 day ago

DEADLINE

in 13 days
View Details
NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.
W6QK Acc-Apg

POSTED

1 day ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
AJ12--Development/Production - Kidney GEC-Specific AAV Vector
Solicitation # 36C24E27Q0009
The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.
Rpo East (36C24E)

POSTED

1 day ago

DEADLINE

in 13 days
View Details
NAICS: 541714
New
Grant
MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Grant
Discovery Gateway to Reproductive Health InnovationThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to establish the Discovery Gateway to Reproductive Health Innovation. This initiative aims to create a comprehensive, open-access web-based visualization platform and knowledgebase to advance research on male and female reproductive health issues, including infertility, uterine fibroids, endometriosis, preeclampsia, and preterm birth. By integrating multi-omic, pharmacogenomic, and clinical data, the Gateway seeks to fill critical knowledge gaps and provide the biomedical community with shared infrastructure to identify biomarkers, drug targets, and disease mechanisms. The primary objective of this project is to catalyze the discovery of new treatments and cures while fostering public-private partnerships and the development of commercial products. This effort aligns with recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. The opportunity is currently listed as a forecast, with administrative oversight provided by the Obstetric and Pediatric Pharmacology and Therapeutics Branch.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking applications under solicitation RFA-AI-28-005 to continue the Immune Tolerance Network. The primary goal of this initiative is the development of tolerogenic therapies targeting autoimmune diseases, allergic diseases and asthma, and immune-mediated consequences of transplantation. The network is tasked with the core functions of designing and conducting clinical trials, performing integrated mechanistic studies, and sharing the resulting data. This federal solicitation was posted on October 20, 2026, and requires responses by January 30, 2027. As a UM1 clinical trial requirement, the project emphasizes a collaborative approach to advancing medical treatments for immune-mediated disorders through rigorous clinical research and analysis.
National Institute Of Allergy And Infectious Diseases

POSTED

3 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is soliciting proposals for the Translational Centers Using Microphysiological Systems for Infectious Diseases under solicitation number RFA-AI-28-012. This initiative aims to establish a consortium of centers focused on refining and validating human tissue models to study infectious diseases and test medical interventions. By leveraging New Approach Methodologies, the program seeks to create in vitro systems that capture human variability and patient-specific characteristics, ultimately accelerating the development of safer treatments while reducing costs and the reliance on laboratory animals. The primary objective is to advance these microphysiological systems to a level of regulatory qualification that encourages adoption by product developers and ensures regulatory acceptance. Interested parties must submit their responses by the deadline of January 30, 2027. This federal opportunity specifically focuses on bridging the gap between current research and regulatory use for infectious disease models, though it is noted that clinical trials are not allowed under this specific funding mechanism.
National Institute Of Allergy And Infectious Diseases

POSTED

3 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
International
Barley Net Blotch Initiative (BNBI) Program 2 – Host and pathogen genetics
Solicitation # PROC-9177507
The Grains Research and Development Corporation is seeking a partner to deliver Program 2 of the Barley Net Blotch Initiative, a five-year national effort to combat the significant economic threat of net blotch in Australian barley. This specific program focuses on host and pathogen genetics to fast-track the development of durable host resistance. Key objectives include providing breeder-deployable validated markers, characterizing resistance sources, conducting pathogenic genomics research, establishing a durability risk-assessment framework, and assessing the feasibility of genome-editing. This solicitation, identified as PROC-9177507, was posted on October 19, 2026, with a response deadline of March 4, 2027. The project is part of a broader strategy involving pathogen surveillance and integrated disease management to reduce the estimated 122 million dollar annual loss caused by yield decreases and grain quality downgrades. Performance of the contract will span multiple major Australian cities, including Canberra, Sydney, Melbourne, Adelaide, Perth, Brisbane, Darwin, and Hobart.
Grains Research and Development Corporation

POSTED

3 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Federal
Pre-Clinical Models of Infectious Diseases
Solicitation # 75N93027R00003
The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a ramp-on solicitation to award multiple IDIQ base contracts for the Preclinical Models of Infectious Diseases program. This initiative aims to expand the existing pool of contractors capable of developing and refining animal and animal replacement models to evaluate medical countermeasures, such as vaccines, therapeutics, and diagnostics. The program bridges the gap between in vitro testing and clinical evaluation, supporting regulatory submissions and the advancement of countermeasures against priority biodefense and emerging infectious agents. Successful offerors will be eligible to compete for task orders across four specific areas: Small Animal Models, Non-Human Primate Models, Animal Replacement and Non-traditional Animal Models, and the Generation and Distribution of Specialized Reagents. The scope of work emphasizes a wide array of pathogens, including pandemic-potential RNA viruses, antimicrobial-resistant infections, fungal diseases, and neglected tropical diseases. Proposals must be submitted electronically via the NIAID eCPS website, and applicants are required to have a valid NIH eRA Commons account for authentication and secure transmission.
National Institutes Of Health Niaid

POSTED

3 days ago

DEADLINE

in about 2 months
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

NAICS: 541715
New
Grant
Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource-Constrained Settings--Implementation Science Network (PATC3H-IN)The Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC3H-IN) is a National Institutes of Health initiative focused on conducting implementation science research to combat adolescent HIV. By developing and testing scalable, low-resource care delivery models in low- and middle-income countries, the network aims to generate robust evidence on HIV incidence, prevention uptake, and viral suppression. These international studies leverage large adolescent populations and innovative, cost-effective service delivery methods to create practice-ready strategies that can be adapted for marginalized and high-burden populations within the United States. The program addresses critical gaps in the U.S. healthcare system where adolescents face similar barriers to care as those in resource-constrained global settings, including poverty, stigma, and fragmented services. Comprising Clinical Research Centers and a Data and Coordinating Center, PATC3H-IN supports the goals of the Ending the HIV Epidemic in the U.S. initiative by accelerating the translation of resilient and cost-conscious care models into domestic practice. This effort is authorized under the Eunice Kennedy Shriver National Institute of Child Health and Human Development to improve overall care outcomes and prevent new HIV acquisitions among at-risk youth.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

2 days ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Grant
CAPSTONE Centers for Multidisciplinary Research in Child Abuse and NeglectThe CAPSTONE Centers for Multidisciplinary Research in Child Abuse and Neglect is a forecast opportunity from the National Institutes of Health under the Department of Health and Human Services. This initiative focuses on child sexual abuse as a critical public health issue, aiming to overcome ethical and methodological barriers to better understand and prevent its lifelong developmental and health consequences. The program emphasizes translational research to create measurable public health impacts rather than solely identifying risk factors. The initiative utilizes a collaborative P50 mechanism to establish national resources for high-quality research. Key areas of focus include evaluating intervention efficacy, conducting longitudinal studies on chronic disease outcomes, researching biological embedding, and improving data infrastructure. The program is managed by the Pediatric Trauma and Critical Illness Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

2 days ago

DEADLINE

N/A
View Details
NAICS: 541715
New
Grant
Learning Disabilities Research CentersThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is forecasting an opportunity to support transdisciplinary research centers dedicated to improving outcomes for children and youth with specific learning disabilities in mathematics, reading, and writing. These centers will prioritize enhancing the identification and classification of these disabilities while exploring their genetic and neurobiological foundations and testing innovative screening and intervention methods. Beyond primary research, the funded centers are expected to leverage their infrastructure to collaborate with key stakeholders and provide project-based mentorship for emerging researchers in the field of learning disabilities. This initiative is authorized under several sections of the U.S. Code to advance the understanding and treatment of these developmental challenges.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

2 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications (U42 Clinical Trial Not Allowed)The National Institutes of Health is seeking applicants to establish Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications. These centers will provide essential resources and testing services to the biomedical community to advance the development of genome editing technologies for treating human diseases. By collaborating with NIH-funded investigators, the centers will evaluate the efficacy and safety of delivery technologies, establish editing thresholds to minimize off-target effects, and determine feasibility within various model systems. The initiative emphasizes the creation of in vivo and in vitro research models, with a specific interest in new approach methodologies and human-biology-based models to complement traditional methods. Testing Centers are expected to develop standardized assays and operating procedures to ensure scientific rigor and reproducibility. While focusing on a limited number of initial projects, these centers will build adaptable core systems designed to support a wide range of diseases and offer fee-for-service resources on a local, regional, and national scale.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Coordinating Center for the Claude D. Pepper Older Americans Independence Centers (OAICs)The National Institute on Aging, under the Department of Health and Human Services, intends to publish a Notice of Funding Opportunity for the Coordinating Center of the Claude D. Pepper Older Americans Independence Centers program. This center will act as a facilitator for site interactions and translate program objectives and findings for scientific and general audiences. The selected entity must possess significant scientific expertise in geriatrics and a proven track record of coordinating complex multi-site projects. This announcement serves as a forecast to allow potential applicants time to establish collaborations before the official solicitation is released. The funding opportunity will utilize the U24 activity code. Interested investigators with expertise in aging research are encouraged to prepare for the upcoming application process.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Program (U19 Clinical Trial Optional)The National Institute on Alcohol Abuse and Alcoholism, under the Department of Health and Human Services, intends to issue a Notice of Funding Opportunity to continue the Collaborative Initiative on Fetal Alcohol Spectrum Disorders. This multidisciplinary research consortium focuses on a wide range of studies, including basic, clinical, translational, diagnostic, intervention, and prevention research aimed at addressing the lifelong physical, cognitive, and behavioral impairments caused by prenatal alcohol exposure. The program seeks to support high-priority needs such as improving early identification and diagnosis, validating interventions, and exploring the mechanisms of alcohol teratogenesis to reduce the incidence of these disorders. Successful projects must demonstrate strong integration with the broader consortium through the use of shared resources, coordinated data activities, and multidisciplinary expertise. This forecast indicates a research program where clinical trials are optional.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

16 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Centers for Research on Neglected Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is establishing the Centers for Research on Neglected Infectious Diseases to combat communicable viral, bacterial, parasitic, and fungal infections. This initiative focuses on the epidemiology, pathogenesis, diagnosis, treatment, and prevention of parasitic neglected infectious diseases within endemic regions. By building sustainable in-country research capacity and expertise, the program aims to identify, contain, and mitigate these diseases at their source to protect global health and reduce the risk of spread within the United States. This opportunity is issued as a forecast by the Department of Health and Human Services and is governed by the Public Health Service Act and Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Interested parties can coordinate with the Division of Microbiology and Infectious Diseases for further information. The program emphasizes a multidisciplinary approach to research and training to address the substantial morbidity and mortality associated with understudied infectious diseases.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

16 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)The National Institutes of Health, under the Department of Health and Human Services, is offering a Phased Innovation Award to advance innovative HIV prevention interventions. This funding opportunity utilizes a two-stage R61/R33 structure to move research from initial development and feasibility testing to larger-scale efficacy and implementation studies. The initial R61 phase focuses on the development, refinement, and pilot testing of novel strategies to address critical scientific and operational questions, ensuring readiness for expanded evaluation across diverse populations. Upon the successful completion of R61 milestones, the R33 phase provides support for expanded testing of interventions and implementation strategies. These studies may evaluate the scalability, sustainability, and clinical management of HIV prevention interventions, specifically including integrated approaches that address alcohol use and related comorbidities. Interested parties can contact the HIV/AIDS and Alcohol Research Program for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)The National Institutes of Health is forecasting a Notice of Funding Opportunity to solicit applications for early to definitive clinical trials. This initiative seeks proposals testing a wide range of interventions, including drugs, devices, biologics, procedures, and behavioral or social interventions, provided they align with the research missions of the participating NIH Institutes, Centers, and Offices. The funding will utilize a bi-phasic, milestone-driven R61/R33 activity code with a maximum project period of seven years. The R61 phase focuses on planning activities, while the R33 phase supports the actual clinical trial. Although applications are not currently being accepted, this notice serves as an advance alert for investigators with expertise in trial design, implementation, and stakeholder engagement to begin developing collaborations and projects.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

23 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Continuation of the Exceptional Longevity Data Management and Coordinating Center (EL DMCC) (U24 Clinical Trial Not Allowed)The National Institute on Aging intends to issue a single U24 cooperative agreement award to support the continued operation and expansion of the Exceptional Longevity Data Management and Coordinating Center. Serving as the central hub for human longevity translational research, the center integrates deeply phenotyped cohorts and multi-omics datasets to enable cross-cohort analyses and collaborative research. Key responsibilities include data harmonization, the implementation of common data standards, and the management of the ELITE Portal, which provides the research community with secure access to analytical tools and cloud-based computational workspaces. The upcoming funding opportunity will require the Coordinating Center to expand its capabilities in artificial intelligence, machine learning, and the integration of diverse datasets across different species. Future objectives include the development of curated target knowledgebases for therapeutic targets, the enhancement of portal interoperability according to FAIR data principles, and the strengthening of community engagement through specialized training and workshops. This notice serves as a forecast to allow potential applicants to establish collaborations before the official solicitation is released.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

28 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Immune Drivers of Autoimmune DiseaseThe National Institute of Allergy and Infectious Diseases seeks to support the Immune Drivers of Autoimmune Disease network to investigate the triggers and early mechanisms of autoimmunity in humans. The primary goal is to develop tools for risk prediction and staging, identify pre-clinical immune mechanisms, and utilize artificial intelligence and big data to prevent autoimmune diseases. This initiative emphasizes the creation of preclinical cohorts and the use of remote recruitment and sampling to advance medical research. The network will be managed by a Coordinating Center responsible for data harmonization, sample sharing, and the administration of an Infrastructure Opportunity Fund for collaborative research projects. This forecast, issued by the National Institutes of Health under the Department of Health and Human Services, establishes a framework for shared infrastructure and steering committee oversight to identify common pathways and prevention opportunities.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

28 days ago

DEADLINE

N/A
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS